

IFW

Dkt. 67705/JPW/GJG/NDP

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Eran Blaugrund et al.

Serial No. : 10/712,958

Filed : November 13, 2003

For : USE OF RASAGILINE WITH OR WITHOUT RILUZOLE TO
TREAT AMYOTROPHIC LATERAL SCLEROSIS

1185 Avenue of the Americas
New York, New York 10036
October 1, 2004

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

In accordance with their duty of disclosure under 37 C.F.R. §1.56, applicants would like to direct the Examiner's attention to the following documents which are listed on Form PTO-1449 (**Exhibit A**) and are also listed below. A copy of the references listed below as items 1-3 are attached hereto as **Exhibit 1-3**.

This Information Disclosure Statement is being submitted pursuant to 37 C.F.R. §1.97(b)(3) before the mailing of a first Office Action on the merits. Thus, this Information Disclosure Statement should be entered and considered.

Applicants : Eran Blaugrund et al.
Serial No.: 10/712,958
Filed : November 13, 2003
Page 2

1. Turner MR, et al., (2001) The King's data base 1990-2000: An analysis of the effect on survival of interventions in ALS. ALS and Other Motor Neuron Disorders, 2(Suppl. 2):43;
2. Traynor BJ, et al., (2001) Riluzole and prognosis in amyotrophic lateral sclerosis: Findings of the Irish amyotrophic lateral sclerosis register over a five year study period 1995-2000. ALS and Other Motor Neuron Disorders, 2(Suppl. 2):43-4; and
3. Wong PC, et al., (1995) An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron diseases characterized by vacuolar degeneration of mitochondria. Neuron, 14:1105-16.


Applicants request that the Examiner review the references and make them of record in the subject application.

If a telephone interview would be of assistance in advancing prosecution of the subject application, applicants' undersigned attorney invites the Examiner to telephone him at the number provided below.

Applicants : Eran Blaugrund et al.
Serial No.: 10/712,958
Filed : November 13, 2003
Page 3


No fee is deemed necessary in connection with the filing of this Information Disclosure Statement. However, if any fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 03-3125.


Respectfully submitted,



John P. White
Registration No. 28,678
Gary J. Gershik
Registration No. 39,992
Attorneys for Applicants
Cooper & Dunham LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400

I hereby certify that this correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to:
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


John P. White Date
Reg. No. 28,678
Gary J. Gershik
Reg. No. 39,992



Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office		Atty. Docket No. 67705/JPW/GJG/NDP		Serial No. 10/772,958	
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)				Applicants: Eran Blaugrund et al.			
				Filing Date November 13, 2003		Group	
U.S. PATENT DOCUMENTS							
Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
FOREIGN PATENT DOCUMENTS							
		Document Number	Date	Country	Class	Subclass	Translation Yes No
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
		Turner MR, et al., (2001) The King's data base 1990-2000: An analysis of the effect on survival of interventions in ALS. <u>ALS and Other Motor Neuron Disorders</u> , 2(Suppl. 2):43; and					
		Traynor BJ, et al., (2001) Riluzole and prognosis in amyotrophic lateral sclerosis: Findings of the Irish amyotrophic lateral sclerosis register over a five year study period 1995-2000. <u>ALS and Other Motor Neuron Disorders</u> , 2(Suppl. 2):43-4;					
		Wong PC, et al., (1995) An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron diseases characterized by vacuolar degeneration of mitochondria. <u>Neuron</u> , 14:1105-16.					
EXAMINER		DATE CONSIDERED					
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

Applicants: Eran Blaugrund et al.
Serial No.: 10/712,958
Filed: November 13, 2003
Exhibit A